FORTIS · NSE
Fortis Healthcare Limited
₹886
-0.01% (-₹0.1)
Prev. close
₹886.1
Volume
19,28,099
Delivery %
75.0%
As of
18 Sept 2026
Price history
Analyst sentiment
Analysts lean bullish
1 analyst stance · last 90 days · one per analyst
Trackable
none in window
Long-Horizon
none in window
Commentary
1 · 1 bull / 0 neutral / 0 bear
Trackable = verdict-bearing calls · Long-Horizon = 1yr+ horizon, verdict pending · Commentary = context, not graded
Analyst opinions
Market commentary · 1 · levels, conditionals, previews, macro & hedged views — context, not graded
| Call | Analyst | Instrument | Verdict | Actions |
|---|---|---|---|---|
| “HSBC sets a target price of ₹1,200 for Fortis Healthcare, implying a 30% upside, as the hospital chain enters a new grow…” | HSBC AnalysisHSBC | Fortis Healthcare | PENDING |
Fundamentals
About Fortis Healthcare Limited
Fortis Healthcare Limited operates as a healthcare delivery service provider in India. The company services in the areas of cardiac science, nephrology, diabetology/endocrinology, foetal medicine, infectious diseases, mental health and behavioral science, oncology, orthopedics, physiotherapy and rehabilitation, rheumatology, urology, nuclear medicine, critical care, emergency and trauma, general surgery, internal medicine, neurointerventional radiology, obstetrics and gynaecology, pediatrics, pediatrics, vascular surgery, and support facilities. It also provides services in the areas of infertility medicine, dental science, endocrine surgery, geriatric medicine, liver transplant and hepatobiliary sciences, neurology, ophthalmology, pain and palliative medicine, pulmonology, thoracic surgery, gastroenterology sciences, dermatology, ENT, haematology, medical generics, neurology, organ transplant, radiology, and transfusion medicines. In addition, the company offers various spectrum integrated healthcare services ranging from clinics to quaternary care facilities and a range of ancillary services, as well as secondary, and tertiary care services. The company's healthcare verticals comprise hospitals, diagnostics, and day care specialty facilities. Fortis Healthcare Limited was incorporated in 1996 and is based in Gurugram, India.
Details
Sector
Healthcare
Industry
Medical Care Facilities
CEO
Dr. Ashutosh Raghuvanshi
Headquarters
Gurugram
Employees
14,649
Website
fortishealthcare.comExchange
View on NSE ↗Key stats
Market cap
₹66,896.84 Cr
P/E ratio (TTM)
64.0
Dividend yield
0.11%
EPS (TTM)
₹13.84
Beta (1Y · daily vs NIFTY 50)
0.81
Beta (5Y · monthly vs NIFTY 50)
1.26
Shares float
48.93 Cr
EPS · quarter ended Jun 2026
₹3.53
Upcoming earnings
13 Nov 2026
Financial Performance
01 · Financials
FY21 growth needs FY20 filings, which the data source doesn't provide.
02 · Earnings Per Share (EPS)
03 · Dividend Profile
Growth compares completed fiscal-year dividend totals on the company's own calendar: April–March (Indian FY), taken from its reported period-ends. Payout ledger: NSE corporate actions.
04 · Operating Efficiency (Growth Rates)
Balance-sheet-based · pre-FY23 not filed in verifiable form
05 · Capital Structure & Asset Utilization
Pre-FY23 not filed in verifiable form
Asset turnover needs a prior year of assets — omitted for the earliest available year.
06 · Asset Base Composition
Pre-FY23 not filed in verifiable form
07 · Debt Level & Coverage
Pre-FY23 not filed in verifiable form
08 · Profit & Loss
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹4,030.12 Cr | ₹5,717.61 Cr | ₹6,297.63 Cr | ₹6,892.92 Cr | ₹7,782.75 Cr | ₹9,127.84 Cr | |
| EBITDA | ₹452.21 Cr | ₹1,411.33 Cr | ₹1,237.80 Cr | ₹1,308.51 Cr | ₹1,547.49 Cr | ₹2,097.86 Cr |
| ₹-109.76 Cr | ₹555.12 Cr | ₹588.73 Cr | ₹598.88 Cr | ₹774.21 Cr | ₹1,041.78 Cr | |
| Diluted EPS | ₹-1.45 | ₹7.35 | ₹7.8 | ₹7.93 | ₹10.26 | ₹13.8 |
09 · Balance Sheet
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹10,866.00 Cr | ₹11,516.00 Cr | ₹12,089.00 Cr | ₹12,971.00 Cr | ₹13,377.00 Cr | ₹15,833.00 Cr | |
| ₹1,530.55 Cr | ₹1,254.93 Cr | ₹925.72 Cr | ₹1,155.02 Cr | ₹2,475.11 Cr | ₹3,472.58 Cr | |
| Stockholders' equity | ₹6,120.00 Cr | ₹6,178.00 Cr | ₹7,242.00 Cr | ₹7,663.00 Cr | ₹8,917.00 Cr | ₹9,896.00 Cr |
Trade receivables, Long-term debt, Current (short-term) debt, Others have filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source doesn’t publish quarterly balance-sheet detail for most NSE-listed companies.
10 · Cash Flow Statement
Annual
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| ₹485.00 Cr | ₹865.00 Cr | ₹822.00 Cr | ₹1,100.00 Cr | ₹1,424.00 Cr | ₹1,601.00 Cr | |
| Investing cash flow | ₹-135.11 Cr | ₹-514.38 Cr | ₹-373.70 Cr | ₹-886.35 Cr | ₹-779.38 Cr | ₹-1,538.41 Cr |
| ₹-143.00 Cr | ₹-517.00 Cr | ₹-471.00 Cr | ₹-86.00 Cr | ₹-714.00 Cr | ₹164.00 Cr | |
| Capital expenditure | ₹-218.51 Cr | ₹-215.49 Cr | ₹-447.24 Cr | ₹-942.47 Cr | ₹-846.94 Cr | ₹-945.53 Cr |
| End cash position | — | ₹66.60 Cr | ₹45.14 Cr | ₹169.66 Cr | ₹99.91 Cr | ₹328.32 Cr |
End cash position has filed figures for only some of the years shown — no further verified source covers the rest, so those years are left blank rather than estimated.
Annual only — the data source has no quarterly cash-flow-statement coverage.
11 · Shareholding Pattern
NSE, quarterly
| Line item | Sep 21–Jun 26(20Q) |
|---|---|
| Promoter | 31.17% |
| Public | 68.83% |
| Employee trusts | 0.00% |
Source: NSE quarterly shareholding-pattern filings, collapsed to periods where the reported percentages held steady — a column spanning several quarters means no change was filed across them. No FII/DII sub-split available from this source — Public includes all non-promoter, non-employee-trust holders.
12 · Peer Comparison
Healthcare
| Company | ||||||||
|---|---|---|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | ₹4.48 L Cr | ₹1,837.3 | 37.0 | 5.36 | 13.7% | 0.06 | +11.9% | +11.4% |
| Divi's Laboratories Limited | ₹2.47 L Cr | ₹9,375 | 83.3 | 14.77 | 15.3% | 0.00 | +12.3% | +53.4% |
| Torrent Pharmaceuticals Limited | ₹1.83 L Cr | ₹4,875 | 76.9 | 21.82 | 25.8% | 1.79 | +21.5% | +37.4% |
| Apollo Hospitals Enterprise Limited | ₹1.26 L Cr | ₹8,944.5 | 60.4 | 13.30 | 20.5% | 0.90 | +15.7% | +13.9% |
| Lenskart Solutions Limited | ₹1.18 L Cr | ₹707.2 | 179.9 | 13.48 | 5.6% | 0.35 | +35.4% | — |
| Zydus Lifesciences Limited | ₹1.13 L Cr | ₹1,160 | 25.3 | 4.18 | 18.6% | 0.46 | +18.4% | +10.7% |
| Cipla Limited | ₹1.10 L Cr | ₹1,376.3 | 32.5 | 3.19 | 11.3% | 0.02 | +2.1% | -11.8% |
| Laurus Labs Limited | ₹1.05 L Cr | ₹1,954 | 96.4 | 19.86 | 16.8% | 0.48 | +22.0% | +111.6% |
| Max Healthcare Institute Limited | ₹1.01 L Cr | ₹1,049.3 | 69.8 | 9.39 | 13.4% | 0.32 | +19.0% | -10.6% |
| Dr. Reddy's Laboratories Limited | ₹97,876.16 Cr | ₹1,185 | 29.6 | 2.60 | 11.4% | 0.21 | +3.2% | -10.4% |
| Manipal Health Enterprises Limited | ₹97,364.22 Cr | ₹738.95 | 146.6 | 11.56 | 7.8% | 1.53 | +18.0% | — |
| Fortis Healthcare Limited | ₹66,896.84 Cr | ₹886 | 64.0 | 6.76 | 10.5% | 0.35 | +17.1% | -8.5% |
Ranked by market cap within Healthcare, same metrics as the Fundamentals screener. Click a column to sort.
Documents
IPO documents
Annual reports
Show all 20
Concall transcripts
Show all 14
Official documents linked from their sources — offer documents as filed with SEBI (sebi.gov.in), annual reports and earnings-call transcripts as published on BSE (bseindia.com) and NSE (nseindia.com). Links open the source's own hosting; nothing is re-hosted here.
Index membership
46 indices
NSE weights are a free-float market-cap-share estimate, not NSE’s own published (and sometimes capped) index weight. BSE weights are BSE’s own published index weight, not an estimate. Indices without weight data are listed without one, in alphabetical order after the weighted ones.